MREO 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-12

• The following table sets forth Mereo’s results of operations for the three months ended March 31, 2026 and 2025.

• The increase in program expenses for setrusumab was primarily driven by recognition of a $2.3 million payable for our share of certain costs related to the cancellation of manufacturing slots by Ultragenyx, partially offset by reductions of, and delays to, investment in manufacturing and ongoing act…

• the recognition of a $1.9 million reduction in expenses in the three months ended March 31, 2026 for amounts received from our depository to reimburse certain expenses incurred by us in respect of our ADR program, whereas the corresponding amount in the prior year was recognized in the three months …

• reductions of approximately $1.4 million driven by delays to investment in pre-commercial activities to lay the foundation for the potential commercial launch of setrusumab in Europe, if approved, and other realized cost savings.

• The benefit from research and development tax credit decreased by $0.1 million, from $0.2 million in the three months ended March 31, 2025 to $0.1 million in the three months ended March 31, 2026. This decrease reflects a lower level of qualifying expenditure in the three months ended March 31, 2026…

相对上期删除的文字 · 来源:10-Q · 2025-11-10

• Comparison of three months ended September 30, 2025 and 2024

• The following table sets forth Mereo’s results of operations for the three months ended September 30, 2025 and 2024.

• The increase in program expenses for setrusumab was primarily driven by amounts due under the manufacturing and supply agreement with our partner, Ultragenyx, as well as ongoing activities related to real-world evidence programs and medical affairs activities in Europe. This is in addition to costs …

• General and administrative expenses also includes $0.8 million in the three months ended September 30, 2025 of pre-commercial activities to lay the foundation for the potential commercial launch of setrusumab in Europe, if approved, including those to support pricing and reimbursement by HTA authori…

• Other income of $0.3 million for the nine months ended September 30, 2025 comprised amounts received from āshibio in connection with the out-licensing of vantictumab, which was acquired in connection with the merger between the Company and Mereo BioPharma 5, Inc.

相对上期新增的文字 · 来源:10-Q · 2026-05-12

• The information set forth in Note 14, Commitments and contingencies, to the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q under the caption “Putative Securities Class Action” is incorporated herein by reference.

相对上期删除的文字 · 来源:10-Q · 2025-11-10

• As of September 30, 2025, we were not a party to any material legal proceedings.